This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in this journal  Topic Collections  • General Rhinology  • Paranasal Sinus Disease  • Pulmonary Diseases  • Pulmonary Diseases, Other  • Liver/ Biliary Tract/ Pancreatic Diseases  • Genetics  • Genetic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Mariano Cimmino, MD; Massimiliano Nardone, MD; Matteo Cavaliere, MD; Angela Plantulli, MD; Angela Sepe, MD; Valeria Esposito, MD; Giuseppina Mazzarella, MD; Valeria Raia, MD

Arch Otolaryngol Head Neck Surg. 2005;131:1097-1101.

Objective  To determine the benefit of nasally inhaled dornase alfa in patients with cystic fibrosis and nasal symptoms.

Design  Double-blind placebo-controlled trial.

Setting  Cystic Fibrosis Regional Center of Campania at the University of Naples "Federico II."

Patients  A total of 24 patients with cystic fibrosis and chronic sinusitis.

Interventions  Patients underwent sinonasal surgery during a 3-year period and received once-daily doses of either dornase alfa (2.5 mg) or hypotonic saline solution (5 mL) beginning 1 month after surgery and for a 12-month period.

Main Outcome Measures  Primary outcomes were nasal-related symptoms and nasal endoscopic appearance; secondary outcomes were forced expiratory volume in 1 second, nasal computed tomography findings, and saccharine clearance test results. Patients were evaluated before and after treatment.

Results  After surgery, all outcomes were significantly improved for each treatment at 1 month (P<.05); primary outcomes were improved at 24 and 48 weeks in the group receiving dornase alfa (P<.05), and at 12 weeks in the group receiving placebo. Secondary outcomes were better in the dornase alfa group (P<.01) than in the placebo group at 12 months except for the saccharine clearance test results. In particular, median relative difference in forced expiratory volume in 1 second between dornase alfa and placebo was significantly improved in the dornase alfa group (P<.01).

Conclusions  Nasally inhaled dornase alfa can be effective in patients with cystic fibrosis and sinonasal disease who do not respond to conventional therapy after surgical treatment. Further studies should be carried out to determine the long-term effect on sinus disease, recurrence of polyps, and quality of life.

Author Affiliations: Departments of Otorhinolaryngology (Drs Cimmino, Nardone, and Cavaliere) and Pediatrics (Drs Plantulli, Sepe, Esposito, Mazzarella, and Raia), University of Naples "Federico II," Naples, Italy.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Sinonasal Disease and Nasal Saline
Baran Acar and Hayriye Karabulut
Arch Otolaryngol Head Neck Surg. 2007;133(6):625.
EXTRACT | FULL TEXT  

Sinonasal Disease and Nasal Saline—Reply
Valeria Raia, Angela Sepe, Mariano Cimmino, Massimiliano Nardone, Matteo Cavaliere, Angela Plantulli, and Giuseppina Mazzarella
Arch Otolaryngol Head Neck Surg. 2007;133(6):625.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cystic Fibrosis Pulmonary Guidelines: Chronic Medications for Maintenance of Lung Health
Flume et al.
Am. J. Respir. Crit. Care Med. 2007;176:957-969.
ABSTRACT | FULL TEXT  

Sinonasal Disease and Nasal Saline
Acar and Karabulut
Arch Otolaryngol Head Neck Surg 2007;133:625-625.
FULL TEXT